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Background: N1,N12-diacetylspermine (DiAcSpm) is excreted 
in the urine of healthy persons, with small individual variations in 
the amount. Some studies revealed that excretion of DiAcSpm was 
frequently and markedly elevated in patients with various cancers, but 
unknown about Non-Small Cell Lung Cancer (NSCLC).
Methods: Urine samples from 179 NSCLC patients (mean age; 66.7 
year-old. Range; 41-87, male;100 female;79), benign thoracic diseases 
(n=26), interstitial pneumonia (n=17) and pleuritis (n=10) treated in 
Tokyo Metropolitan Komagome Hospital between December 2003 to 
September 2006 were collected. Urinary DiAcSpm level was ana-
lyzed by ELISA and compared with that of healthy volunteers (n=52, 
0.15±0.05μmol/g creatinine).
Results: The mean urine DiAcSpm level of whole NSCLC patients 
was 0.34±0.60μmol/g creatinine (p<0.05). The mean urine DiAc-
Spm level of 126 patients with adenocarcinoma and 41 patients with 
squamous cell carcinoma was 0.25±0.20(p<0.001), 0.56±1.06(p<0.01), 
respectively. The mean urinary DiAcSpm level among NSCLC patients 
at various pathological stages was 0.24±0.15 in IA (n=84), 0.27±0.17 
in IB (n=33), 0.32±0.23 in II (n= 18), 0.31±0.24 in III (n=37), and 
0.70±0.58 in IV (n=7), respectively. Urinary DiAcSpm levels were 
low in benign thoracic diseases (0.17±0.05, p=0.35), but high in 
patients with interstitial pneumonia (0.32±0.28, p<0.001) and pleuritis 
(0.21±0.06, p<0.05).
Conclusion: Urinary DiAcSpm level of NSCLC patients is higher than 
healthy volunteers and benign thoracic diseases. So, DiAcSpm may 
be useful as a tumor marker for NSCLC because that urine samples 
may be readily collected non-invasively, and measurement of urinary 
DiAcSpm levels is rapid and inexpensive. 
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Objective: For the purpose of early detection of lung cancer, popula-
tion based lung cancer screening program with sputum cytology has 
been conducted since I987 in Chiba prefecture in Japan. Sputum cytol-
ogy has been proved to be effective to detect central type squamous 
cell carcinomas (SCC), but has not been proved to be effective to detect 
peripheral type SCC. In this series, we analyzed its efﬁcacy to detect 
peripheral type SCC and compared to their chest x-ray ﬁndings of the 
cases in this program. 
Methods: In our institute, a total of 91,945 participants in the high-risk 
group for lung carcinomas were involved in our study between 1993 
and 2001. Cases smoking pack-year 30 or more were included in the 
high-risk group for SCCs. Sputum cytology was performed for this 
group after modiﬁed Saccomano’s method, and chest x-ray examina-
tion including CT and bronchoscopy were carried out to conﬁrm the 
diagnosis. We analyzed cytological ﬁndings of cases of peripheral SCC 
detected during this period, and compared with that of central SCC or 
their chest x-ray ﬁndings. 
Results: During this period, 144 lung cancers were found by this 
program (total detection rate: 0.16 %). Among them, 21 cases (14.6%) 
were peripheral SCCs. They were all male, and mean age was 72.0 yrs. 
They were all heavy smokers and mean smoking indices were 1079. 
Clinical stages of them were 14 cases in stage I, 7 cases in more than 
stage II, and severe lung emphysemas were combined in 5 cases (24%). 
At the time of sputum examination, positive plain chest x-ray ﬁnd-
ings were observed in 9 cases. In three cases positive plain chest x-ray 
ﬁndings were obtained during follow up period by follow up sputum 
and chest x-ray examinations. In nine cases (43%), only sputum cytol-
ogy was positive or suspicious at the time of sputum examination, and 
bronchoscopy or chest CT showed negative studies. In these cases, 
lesions were detected during follow up period by chest CT examina-
tion. Compared with central SCCs, numbers of atypical squamous cells 
appeared in the sputum of peripheral SCCs were small and incoherent. 
Bright yellow keratinizing atypical squamous cells were dominant in 
peripheral SCCs. 
Conclusion: With this program, nine cases out of 144 detected lung 
cancers were so-called occult peripheral SCCs in which were negative 
study by bronchoscopy or chest CT examination. Analysis of atypi-
cal squamous cells in the sputum of the SCC patients was effective to 
estimate the sites of lesions.
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Background: The diagnosis of malignant pleural effusion is clinically 
important because the prognosis of patients with malignant pleural 
effusion is poor and similar to patients with stage IV disease. But, 
the diagnosis will be difﬁcult if cytologic testing is negative and the 
pleural effusion is transudate and nonbloody exudate. This study was 
performed to investigate whether aberrant methylation of p16 and 
retinoic acid receptor b2 (RARB2) gene in pleural ﬂuid is useful for the 
diagnosis of malignant pleural effusions. 
Methods: Pleural effusions collected from 26 lung cancer patients of 
a biopsy-proven pleural invasion were investigated for the aberrant 
promoter methylation of p16 and RARB2 using a methylation-speciﬁc 
PCR. Pleural ﬂuid was obtained by thoracentesis or chest tube, and 
then DNA was extracted. After DNA was modiﬁed by treatment with 
sodium bisulfate, methylation-speciﬁc PCR (MSP) was done. 
Results: 19 cases were male patients and 7 cases were female. His-
tologic types were 12 adenocarcinomas, 7 small cell carcinomas, 6 
squamous cell carcinomas, and 1 non-classiﬁable non-small cell lung 
cancer(NSCLC). Aberrant methylation of p16 and RARB2 gene were 
noted in 7 cases (26.9%) and 12 cases (46.1%) respectively. Together 
with 2 genes, aberrant methylations were detected in 15 cases (57.7%). 
In adenocarcinoma, squamous cell carcinoma, small cell carcinoma, 
and NSCLC aberrant methylations were detected in 8 out of 11 
(72.7%), 3 out of 5 (60%), 3 out of 7 (42.9%), and 0 out of 1 (0%) 
cases respectively. 
Conclusion: This investigation demonstrates that detection of aberrant 
methylation of p16 or RARB2 gene showed relatively low sensitive 
methods to diagnose malignant effusions. But it also suggests if mul-
tiple genes are used for speciﬁc types of histology the results would be 
better.
